Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial Meeting Abstract
| Authors: | Pook, D.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; Gurney, H.; Kessler, E. R.; Retz, M.; George, S.; Escudier, B.; Zhang, J.; Simsek, B.; Scheffold, C.; Motzer, R. J.; Choueiri, T. K.; Apolo, A. B. |
| Abstract Title: | Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial |
| Meeting Title: | 48th Annual Scientific Meeting of the Clinical Oncology Society of Australia (COSA) |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 17 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2021 Nov 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-11-01 |
| Start Page: | 131 |
| Language: | English |
| ACCESSION: | WOS:000717281500188 |
| PROVIDER: | wos |
| PUBMED: | 34766444 |
| DOI: | 10.1111/ajco.13716 |
| Notes: | Meeting Abstract: 243 -- Source: Wos |
